Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.49 |
| ▸ | DRD2 | P14416 | 11/20 | 0.49 |
| ▸ | HTR2A | P28223 | 11/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268805 | 0.86 | HTR1A (0.55) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL4870876 | 0.85 | HTR1A (0.56) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL5669383 | 0.83 | HTR1A (0.51) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL3517324 | 0.80 | HTR1A (0.52) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL3521966 | 0.79 | DRD2 (0.53) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL267610 | 0.77 | HTR1A (0.52) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL20456303 | 0.77 | HTR1A (0.48) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL4350205 | 0.75 | HTR1A (0.50) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL9379524 | 0.74 | HTR1A (0.48) | HTR1ADRD2HTR2AKCNH2KDM4E | |
| SCHEMBL8242911 | 0.74 | HTR1A (0.48) | HTR1ADRD2HTR2AKCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108508-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| US-20240139179-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2024-05-02 | — | — | US | claimed |
| US-20210052577-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2021-02-25 | — | — | US | claimed |
| US-20200253965-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-08-13 | — | — | US | claimed |
| US-20200038396-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-02-06 | — | — | US | claimed |
| US-20190231774-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-08-01 | — | — | US | claimed |
| US-20180353503-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2018-12-13 | — | — | US | claimed |
| US-20180161323-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2018-06-14 | — | — | US | claimed |
| US-20170333425-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-11-23 | — | — | US | claimed |
| US-20170128442-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-05-11 | — | — | US | claimed |
| US-20150105402-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2015-04-16 | — | — | US | claimed |
| US-20140296250-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2014-10-02 | — | — | US | claimed |
| US-20140057922-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2014-02-27 | — | — | US | claimed |
| US-20130203771-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2013-08-08 | — | — | US | claimed |
| US-20130012520-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2013-01-10 | — | — | US | claimed |
| US-20120142699-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2012-06-07 | — | — | US | claimed |
| US-8133893-B2 | Trazodone and trazodone hydrochloride in purified form | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2012-03-13 | — | — | US | claimed |
| EP-2178850-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2010-04-28 | — | — | EP | claimed |
| US-20100056539-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIM. RIUM. ANG. FRANC. A.C.R.A.F.S.P.A. (IT) | 2010-03-04 | — | — | US | claimed |
| WO-2009019133-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-02-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056539-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, OPRM1, OPRK1 | HTR1A 6/4885DRD2 54/4885HTR2A 24/4885 |
| US-20210052577-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, OPRK1, OPRM1 | HTR1A 6/4885DRD2 17/4885HTR2A 35/4885 |
| US-20170333425-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 52/4885HTR2A 27/4885 |
| US-20130012520-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 52/4885HTR2A 27/4885 |
| US-20180353503-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 52/4885HTR2A 27/4885 |
| US-20170128442-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 52/4885HTR2A 27/4885 |
| US-20190231774-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 52/4885HTR2A 27/4885 |
| US-20140296250-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 52/4885HTR2A 27/4885 |
| US-20120142699-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 52/4885HTR2A 27/4885 |
| US-20200253965-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 52/4885HTR2A 27/4885 |
| US-20130203771-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 52/4885HTR2A 27/4885 |
| US-20140057922-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, OPRK1, OPRM1 | HTR1A 5/4885DRD2 52/4885HTR2A 28/4885 |
| US-20200038396-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 55/4885HTR2A 27/4885 |
| US-20240139179-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 52/4885HTR2A 27/4885 |
| US-20180161323-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, POLL, OPRM1 | HTR1A 6/4885DRD2 52/4885HTR2A 27/4885 |
| US-20260108508-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | HTR1A, HTR3A, HTR2C | HTR1A 1/4885DRD2 45/4885HTR2A 5/4885 |
| US-20150105402-A1 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | OPRD1, OPRK1, OPRM1 | HTR1A 5/4885DRD2 52/4885HTR2A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.